These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Imipenem resistant metallo beta lactamase producing Pseudomonas aeruginosa. Chacko B; Varaiya A; Dedhia B Indian J Med Microbiol; 2008; 26(4):398. PubMed ID: 18974504 [No Abstract] [Full Text] [Related]
29. Metallo-beta-lactamase-producing imipenem-resistant Pseudomonas aeruginosa clinical isolates in a university teaching hospital in Malaysia: detection of IMP-7 and first identification of IMP-4, VIM-2, and VIM-11. Khosravi Y; Tee Tay S; Vadivelu J Diagn Microbiol Infect Dis; 2010 Jul; 67(3):294-6. PubMed ID: 20462725 [TBL] [Abstract][Full Text] [Related]
30. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program. Turner PJ Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798 [TBL] [Abstract][Full Text] [Related]
31. Is There a Carbapenem MIC Cutoff Value That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem Non-Susceptible Pseudomonas and Acinetobacter Isolates? Tamma PD; Wang R; Lewis S; Opene BNA; Simner PJ Infect Control Hosp Epidemiol; 2017 Nov; 38(11):1378-1379. PubMed ID: 28965496 [No Abstract] [Full Text] [Related]
32. Spread of efflux pump-overexpressing, non-metallo-beta-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with blaVIM endemicity. Pournaras S; Maniati M; Spanakis N; Ikonomidis A; Tassios PT; Tsakris A; Legakis NJ; Maniatis AN J Antimicrob Chemother; 2005 Oct; 56(4):761-4. PubMed ID: 16115825 [TBL] [Abstract][Full Text] [Related]
33. Molecular epidemiology of clinical Pseudomonas aeruginosa isolates carrying IMP-1 metallo-beta-lactamase gene in a University Hospital in Turkey. Ozgumus OB; Caylan R; Tosun I; Sandalli C; Aydin K; Koksal I Microb Drug Resist; 2007; 13(3):191-8. PubMed ID: 17949306 [TBL] [Abstract][Full Text] [Related]
34. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms. Livermore DM; Yang YJ J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657 [TBL] [Abstract][Full Text] [Related]
35. Supplementation of growth media with Zn2+ facilitates detection of VIM-2-producing Pseudomonas aeruginosa. Giakkoupi P; Vourli S; Polemis M; Kalapothaki V; Tzouvelekis LS; Vatopoulos AC J Clin Microbiol; 2008 Apr; 46(4):1568-9. PubMed ID: 18287311 [No Abstract] [Full Text] [Related]
36. Metallo-beta-lactamase VIM-2 in clinical isolates of Pseudomonas aeruginosa from Portugal. Cardoso O; Leitão R; Figueiredo A; Sousa JC; Duarte A; Peixe LV Microb Drug Resist; 2002; 8(2):93-7. PubMed ID: 12118523 [TBL] [Abstract][Full Text] [Related]
37. Emergence of Imipenem-Resistant Pseudomonas aeruginosa Clinical Isolates from Egypt Coharboring VIM and IMP Carbapenemases. El-Domany RA; Emara M; El-Magd MA; Moustafa WH; Abdeltwab NM Microb Drug Resist; 2017 Sep; 23(6):682-686. PubMed ID: 28085553 [TBL] [Abstract][Full Text] [Related]
38. Increasing prevalence of imipenem-resistant Pseudomonas aeruginosa and molecular typing of metallo-beta-lactamase producers in a Korean hospital. Kim IS; Lee NY; Ki CS; Oh WS; Peck KR; Song JH Microb Drug Resist; 2005; 11(4):355-9. PubMed ID: 16359195 [TBL] [Abstract][Full Text] [Related]
39. Outbreak by meropenem-resistant Pseudomonas aeruginosa producing IMP-6 metallo-beta-lactamase in a Korean hospital. Ryoo NH; Lee K; Lim JB; Lee YH; Bae IK; Jeong SH Diagn Microbiol Infect Dis; 2009 Jan; 63(1):115-7. PubMed ID: 18993011 [TBL] [Abstract][Full Text] [Related]
40. Nosocomial outbreak of meropenem resistant Pseudomonas aeruginosa infections in a cancer centre. Krcméry V; Trupl J J Hosp Infect; 1994 Jan; 26(1):69-71. PubMed ID: 7910185 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]